Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Glycopyrronium bromide (Seebri® Breezhaler®) is recommended as an option for use within NHS Wales as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease |
|||
|
|||
Medicine details |
|||
| Medicine name | glycopyrronium bromide (Seebri Breezhaler®) | ||
| Formulation | 44 micrograms inhalation powder | ||
| Reference number | 1455 | ||
| Indication | Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease |
||
| Company | Novartis Pharmaceuticals UK Ltd | ||
| BNF chapter | Respiratory system | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 0713 | ||
| NMG meeting date | 20/02/2013 | ||
| AWMSG meeting date | 20/03/2013 | ||
| Ratification by Welsh Government | 22/05/2013 | ||
| Date of issue | 22/05/2013 | ||
| Date of last review | November 2022 | ||
| Further information This appraisal recommendation was reviewed in November 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations |
|||